Radiance to begin major restenosis trial in US
This article was originally published in Clinica
Radiance Medical Systems, an Irvine, California-based developer of radiation delivering catheters, is to begin a major US trial of its RDX system on patients with in-stent restenosis of coronary arteries. The FDA has granted the company an investigational device exemption conditional upon it providing additional technical information.
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.